DPP-4的基因组学研究进展与DPP-4抑制剂的临床应用

二肽基肽酶IV(DPP-4)是一种分布广泛的膜相关性丝氨酸蛋白酶,能够影响糖代谢、脂质代谢、免疫调节、神经调节、信号转导、癌症发展等多种生理功能。随着全基因组关联研究(GWAS)的发展,DPP-4基因的基因多态性,主要是单核苷酸多态性已被证实影响血脂水平和mRNA表达,还影响心血管疾病的易感性,可能与DPP-4抑制剂在血脂紊乱和心血管疾病方面的疗效具有密切关系,这在2型糖尿病的治疗中具有重要意义。本文对国内外所有关于DPP-4基因多态性的研究进行综述,并在此基础上探讨其对DPP-4抑制剂在2型糖尿病治疗中的影响。

Progress in DPP-4 genomics research and clinical application of DPP-4 inhibitor

Dipeptidyl peptidase IV (DPP-4), a membrane associated serine protease, influences various physiological activities, such as plasma glucose, lipid metabolism, inflammation, neuroregulation, signaling, development of cancer, etc. With the development of genome-wide association studies (GWAS), genetic polymorphism (mainly the single nucleotide polymorphism) of the DPP-4 gene has been shown to influence the plasma lipid levels, the DPP-4 gene expression, and the susceptibility to cardiovascular disease, which may be associated with the lipid and cardiovascular outcomes of DPP-4 inhibitors in the treatment of type 2 diabetes. We reviewed all the investigations about the polymorphism of DPP-4 gene, and analyzed its association with DPP-4 inhibitors.